West Virginia 2025 Regular Session

West Virginia Senate Bill SB92

Introduced
2/12/25  
Refer
2/12/25  
Report Pass
2/21/25  
Engrossed
2/26/25  
Refer
2/27/25  

Caption

Glucagon for Schools Act

Impact

The Glucagon for Schools Act significantly alters how schools handle diabetes-related emergencies. By facilitating the accessibility of glucagon in schools, the bill aims to ensure that students with diabetes receive timely and appropriate care, which could be life-saving. The legislation also establishes training requirements for school personnel to recognize and respond to diabetes-related emergencies effectively. This proactive approach is likely to lead to improved health outcomes for students with chronic conditions, particularly diabetes, within the school environment.

Summary

Senate Bill 92, also known as the Glucagon for Schools Act, aims to enhance the emergency care available to students with diabetes in West Virginia schools. The bill allows licensed health care providers to prescribe undesignated glucagon, a critical medication needed for treating severe hypoglycemic reactions, in the name of a school district. This legislation mandates that schools maintain a supply of undesignated glucagon and ensures that trained school personnel can administer it when necessary. Furthermore, the bill outlines the required procedures for notifying emergency services and health providers following the administration of glucagon.

Sentiment

General sentiment regarding SB92 appears to be largely positive, particularly among parents, healthcare providers, and educational professionals who recognize the importance of providing immediate medical care to students with diabetes. Supporters argue that the bill addresses a critical need for safety measures in schools and promotes a healthier environment. However, there may be some concerns about the adequacy of training for school personnel and the resources required to implement the program effectively.

Contention

Despite the general support, notable points of contention may arise regarding liability protections for school employees and the adequacy of training. The bill provides certain legal protections for school staff administering glucagon, which some might view as crucial to encouraging staff participation in student care initiatives. Others, however, may argue that this could lead to inadequate training or care, as the responsibility for health outcomes now extends to non-medical personnel. These discussions reflect broader concerns about the intersection of education, healthcare, and liability in the context of student safety.

Companion Bills

No companion bills found.

Similar Bills

MA H671

Relative to undesignated glucagon rescue therapies in schools

FL H0597

Diabetes Management in Schools

KY HB75

AN ACT relating to undesignated glucagon.

KY HB174

AN ACT relating to undesignated glucagon.

NJ A1882

Concerns administration of ready-to-use undesignated glucagon rescue therapy in public schools.

TX HB2891

Relating to the use of glucagon medication on certain public and private school campuses.

TX SB2535

Relating to the use of prescription glucagon medication on public and private school campuses.

VA SB1303

Student diabetes medical management plans; School Health Services Committee to conduct a review.